1. Home
  2. STVN vs VRNA Comparison

STVN vs VRNA Comparison

Compare STVN & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • VRNA
  • Stock Information
  • Founded
  • STVN 1949
  • VRNA 2005
  • Country
  • STVN Italy
  • VRNA United Kingdom
  • Employees
  • STVN N/A
  • VRNA N/A
  • Industry
  • STVN Containers/Packaging
  • VRNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • STVN Consumer Discretionary
  • VRNA Health Care
  • Exchange
  • STVN Nasdaq
  • VRNA Nasdaq
  • Market Cap
  • STVN 6.6B
  • VRNA 7.8B
  • IPO Year
  • STVN 2021
  • VRNA 2017
  • Fundamental
  • Price
  • STVN $23.20
  • VRNA $92.20
  • Analyst Decision
  • STVN Buy
  • VRNA Strong Buy
  • Analyst Count
  • STVN 6
  • VRNA 7
  • Target Price
  • STVN $25.08
  • VRNA $97.57
  • AVG Volume (30 Days)
  • STVN 294.9K
  • VRNA 1.4M
  • Earning Date
  • STVN 08-05-2025
  • VRNA 08-07-2025
  • Dividend Yield
  • STVN 0.26%
  • VRNA N/A
  • EPS Growth
  • STVN N/A
  • VRNA N/A
  • EPS
  • STVN 0.50
  • VRNA N/A
  • Revenue
  • STVN $1,215,562,040.00
  • VRNA $118,535,000.00
  • Revenue This Year
  • STVN $8.69
  • VRNA $891.79
  • Revenue Next Year
  • STVN $10.67
  • VRNA $78.94
  • P/E Ratio
  • STVN $48.09
  • VRNA N/A
  • Revenue Growth
  • STVN 3.81
  • VRNA N/A
  • 52 Week Low
  • STVN $16.56
  • VRNA $14.14
  • 52 Week High
  • STVN $25.75
  • VRNA $94.45
  • Technical
  • Relative Strength Index (RSI)
  • STVN 49.43
  • VRNA 78.05
  • Support Level
  • STVN $22.70
  • VRNA $82.18
  • Resistance Level
  • STVN $24.80
  • VRNA $93.74
  • Average True Range (ATR)
  • STVN 1.09
  • VRNA 3.21
  • MACD
  • STVN -0.03
  • VRNA 0.89
  • Stochastic Oscillator
  • STVN 50.79
  • VRNA 92.52

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About VRNA Verona Pharma plc

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Share on Social Networks: